Showing 1 to 3 of 3 results


EMA Rejects Alzheimer's Drug Donanemab Due to Safety Concerns
The European Medicines Agency (EMA) rejected Eli Lilly's Alzheimer's drug, donanemab, due to concerns about deadly side effects, impacting 7 million Europeans with Alzheimer's despite its 35% efficacy in slowing dementia progression in trials; the decision contrasts with the eventual approval of a s...
EMA Rejects Alzheimer's Drug Donanemab Due to Safety Concerns
The European Medicines Agency (EMA) rejected Eli Lilly's Alzheimer's drug, donanemab, due to concerns about deadly side effects, impacting 7 million Europeans with Alzheimer's despite its 35% efficacy in slowing dementia progression in trials; the decision contrasts with the eventual approval of a s...
Progress
40% Bias Score


EMA Recommends Approval of Alzheimer's Drug Lecanemab
The European Medicines Agency (EMA) recommends approving Lecanemab, an Alzheimer's drug, for early-stage patients with mild cognitive impairment or mild dementia after a previous rejection due to safety concerns; the drug only slightly slows disease progression and is suitable for a small patient su...
EMA Recommends Approval of Alzheimer's Drug Lecanemab
The European Medicines Agency (EMA) recommends approving Lecanemab, an Alzheimer's drug, for early-stage patients with mild cognitive impairment or mild dementia after a previous rejection due to safety concerns; the drug only slightly slows disease progression and is suitable for a small patient su...
Progress
48% Bias Score

EMA Recommends Approval of Alzheimer's Drug Lecanemab
The European Medicines Agency (EMA) again recommends approving Lecanemab, an Alzheimer's drug, for early-stage patients after previously rejecting it due to safety concerns; a new analysis shows benefits outweigh risks in a specific patient subgroup; the drug is already approved in the USA.

EMA Recommends Approval of Alzheimer's Drug Lecanemab
The European Medicines Agency (EMA) again recommends approving Lecanemab, an Alzheimer's drug, for early-stage patients after previously rejecting it due to safety concerns; a new analysis shows benefits outweigh risks in a specific patient subgroup; the drug is already approved in the USA.
Progress
40% Bias Score
Showing 1 to 3 of 3 results